OakChart

Filana Therapeutics Inc

FLNAHealthcare·Biotechnology·USA·Nano·NASD·Nov 12 • 3:59 PM ET

0.45-0.03 (-7.05%)
2026-11-13 05:50 CET
Market cap
$22.52M
Revenue, TTM
0.00 USD m
Net income, TTM
-42.20 USD m
Free cash flow, TTM
-29.13 USD m
EPS diluted, TTM
-0.87
Price / earnings
-
Compare

Price

FLNA against its 20, 50 and 200-day averages
Terms2050200BeatEarnings
Patternshover a marker to name it
Sales mean, own scale
RS 0Sales 0.00Price0.000.501.001.502.002.5047.2M94.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26FLNAclose 0.4520-day 0.5950-day 0.72200-day 1.280.45

87.0% under the 52-week high of 3.45 on 26 Nov 2025. 52-week low 0.43 on 6 Nov 2026. Last 15 sessions, 60.5% high to low

Volume 0.22× normal · the line is the 50-bar volume average

Setup. RS line 0
CANSLIM 2 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); Return on Equity: Over +15% — not on the tape: EPS Growth Next Year: High (>25%)
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200

Profile

FLNA
52-week range, 1% of the way up
0.433.45

Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Employees20
IPOJul 14, 2000
Beta-0.44
ATR, 14d0.05
Rel volume0.22
Short float11.64%
Insider own2.88%
Inst own24.94%

Snapshot

6 groups

Valuation

Index-
Market Cap$22.52M
Enterprise Value-55.72M
Income-42.20M
Sales0.00M
Book / share1.16
Cash / share1.56
Dividend Est.-
Dividend TTM-
Dividend Ex-DateDec 13, 2012
Dividend Gr. 3/5Y- -
Payout-
Employees20
IPOJul 14, 2000

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales-
Price / book0.39
Price / cash0.29
Price / free cash flow-
Value / cash profit-
Value / sales-
Quick Ratio1.91
Current Ratio1.91
Debt / equity0.00
Long-term debt / equity0.00
Options and shortYes / Yes

Earnings

Earnings / share-0.87
Earnings next year-
Earnings next quarter-0.22
Earnings this year56.38%
Earnings next year-
Earnings growth, 5 years-
Past earnings growth0.23% -50.67%
Past sales growth- -
Earnings vs last year60.29%
Sales vs last year-
Earnings vs last quarter1.07%
Sales vs last quarter-
EarningsNov 05 BMO
Surprise10.20% -

Ownership

Insiders own2.88%
Insider trades38.15%
Institutions own24.94%
Institution trades-3.40%
Return on assets-36.73%
Return on equity-60.48%
Return on capital-72.79%
Gross Margin-
Operating margin-
Profit Margin-
20-day average-23.74%
50-day average-37.86%
200-day average-65.13%

Technical

Shares out50.07M
Shares floating48.82M
Short / float11.64%
Short ratio2.82
Short interest5.68M
52-week high3.45 -87.0%
52-week low0.43 +5.4%
Volatility9.07% 8.48%
Average range0.05
Strength index29.65
Market sensitivity-0.44
Relative volume0.22
Avg Volume2.01M
Volume432,542

Performance

Perf Week-0.67%
Perf Month-38.76%
Perf Quarter-50.95%
Perf Half Y-63.87%
Perf YTD-77.37%
Perf Year-86.26%
Perf 3Y-97.72%
Perf 5Y-99.35%
Perf 10Y-90.00%
Recommendation1.00
Target Price6.50
Prev Close0.48
Price0.45
Change %-7.07%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
Nov 26, 2024DowngradeH.C. WainwrightBuy → Neutral
Oct 08, 2024UpgradeH.C. WainwrightNeutral → Buy$116+25,792.9%
Jul 01, 2024DowngradeH.C. WainwrightBuy → Neutral
Nov 16, 2022DowngradeB. Riley SecuritiesBuy → Neutral$44+9,721.4%
Jul 15, 2021DowngradeCantor FitzgeraldOverweight → Neutral$100+22,221.4%
Jul 07, 2021ReiteratedMaxim GroupBuy$80 → $190+42,310.7%
Apr 27, 2021InitiatedB. Riley SecuritiesBuy$78+17,310.7%
Feb 16, 2021ReiteratedH.C. WainwrightBuy$20 → $66+14,632.1%
Oct 23, 2020InitiatedCantor FitzgeraldOverweight$24+5,257.1%
Sep 23, 2020UpgradeH.C. WainwrightNeutral → Buy$20+4,364.3%

Peers

Mkt cap
TickerCompanyMkt cap
ANVSAnnovis Bio Inc36.16M
CGTXCognition Therapeutics Inc64.31M
INMBINmune Bio Inc32.50M
ABOSAcumen Pharmaceuticals Inc15.77M
CRVOCervoMed Inc27.69M
PMNProMIS Neurosciences Inc31.21M
ACIUAC Immune SA217.80M
PRTAProthena Corp Plc422.61M
ALZNAlzamend Neuro Inc6.27M
BIIBBiogen Inc37.03B

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Barry RichardPresident & CEOSep 29 '26Buy0.90206,813186,1321,237,964Oct 01 07:57 AM
Barry RichardPresident & CEOSep 30 '26Buy0.92100,00092,0001,337,964Oct 01 07:57 AM
Barry RichardPresident & CEOSep 28 '26Buy0.8493,09178,1961,031,151Sep 30 04:03 PM
Anderson Robert Eugene JrDirectorNov 24 '25Buy2.908,60024,9408,600Nov 25 04:06 PM
Barry RichardPresident & CEONov 20 '25Buy2.76150,000414,000938,060Nov 24 04:02 PM
Barry RichardPresident & CEONov 19 '25Buy2.7573,385201,809788,060Nov 20 05:39 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
VXFVanguard Extended Market Index ETFAUM: 30.79B
VHTVanguard Health Care ETFAUM: 21.54B
IWCiShares Micro-Cap ETFAUM: 1.23B

News

latest 14 of 200
  • Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board (GlobeNewswire)
  • Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update (GlobeNewswire) -21.15%
  • Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells (GlobeNewswire)
  • Filana Therapeutics to Participate in the 2026 Maxim Growth Summit (GlobeNewswire)
  • Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy (GlobeNewswire) +39.28%
  • Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
  • Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Filana Therapeutics Reports Q1 2026 Financial Results and Business Update (GlobeNewswire) -5.56%
  • Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII (GlobeNewswire)
  • Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data (GlobeNewswire)
  • Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) -6.70%
  • Cassava Announces Closure of U.S. Department of Justice Investigation (GlobeNewswire)
  • Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease (GlobeNewswire)
  • HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.220-0.245-0.2500.000.002
2026Q22026-07-29-0.180-0.225-0.1780.000.002
2026Q12026-05-07-0.210-0.230-0.2140.000.001
2025Q42026-03-12-0.260-0.300-0.2600.000.001
2025Q32025-11-12-0.220-0.270-0.2240.000.001
2025Q22025-08-14-0.920--0.9160.00--
2025Q12025-05-08-0.480--0.4850.00--
2024Q42025-03-03-0.570-0.583-0.5740.000.003
2024Q32024-11-07-0.580-0.730-0.5820.000.003
2024Q22024-08-080.130-0.4070.1330.000.003
2024Q12024-05-10-0.430-0.460-0.4250.000.002
2023Q42024-02-28-0.500-0.520-0.4960.000.002
2023Q32023-11-07-0.610-0.775-0.6110.000.002
2023Q22023-08-03-0.630-0.590-0.6310.000.002
2023Q12023-05-01-0.580-0.555-0.5820.000.002
2022Q42023-02-28-0.470-0.560-0.4690.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.270-0.310-0.2660.000.00
2020FY-0.240-0.203-0.2430.000.00
2021FY-0.820-0.805-0.8220.000.00
2022FY-1.900-1.987-1.8970.000.00
2023FY-2.320-2.340-2.3180.000.00
2024FY-1.460-0.863-1.4620.000.00
2025FY-1.880-1.930-1.8800.000.00
2026FY--0.820--0.00
2027FY--1.190---
2028FY--1.180---
2029FY--1.230---
2030FY--0.490--72.84

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-051000.000.000.00
2026Q4S2026-07-291000.000.000.00
2026Q4S2026-05-071000.000.000.00
2026Q4S2026-03-121000.000.000.00
2026Q4S2025-11-121000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4S2025-11-091000.000.000.00
2026Q4S2025-11-081000.000.000.00
2026Q4S2025-11-071000.000.000.00
2026Q4S2025-11-061000.000.000.00
2026Q4S2025-11-051000.000.000.00
2026Q4R2026-11-05100-0.27-0.27-0.27
2026Q4R2026-10-12100-0.27-0.27-0.27

Estimate history

EPS, annual-1.82-0.614-0.266-0.243-0.822-1.897-2.318-1.462-1.884-0.8728
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.582-0.574-0.485-0.916-0.224-0.26-0.214-0.178-0.221
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual6.59617.21921.84235.23840.01741.73642.23748.20348.30850.068
Period201720182019202020212022202320242025MRQ
Shares, quarterly47.97648.20348.30848.30848.30848.30848.30848.30850.068
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A1.110.941.131.531.300.530.020.060.07
Gross Profit-1.11-0.94-1.13-1.53-1.30-0.53-0.02-0.06-0.07
Selling, General and Administrative Excl. Other44.2894.45150.21104.4379.6236.2311.019.636.59
Research and Development15.5726.5969.6489.4268.9328.717.296.302.97
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-45.39-95.39-151.35-105.96-80.92-36.77-11.03-9.69-6.66
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense2.100.00-118.080.000.000.000.00--
Net Income Before Taxes-42.20-90.97-24.34-97.22-76.25-32.38-6.33-4.63-6.56
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-42.20-90.97-24.34-97.22-76.25-32.38-6.33-4.63-6.56
Net Income From Continuing Operations-42.20-90.97-24.34-97.22-76.25-32.38-6.33-4.63-6.56
Net Income-42.20-90.97-24.34-97.22-76.25-32.38-6.33-4.63-6.56
EPS (Recurring)-0.84-1.88-3.24-2.32-1.90-0.82-0.24-0.27-0.61
EPS (Basic, Before Extraordinaries)-0.87-1.88-0.53-2.32-1.90-0.82-0.24-0.27-0.61
EPS (Diluted)-0.87-1.88-1.46-2.32-1.90-0.82-0.24-0.27-0.61
EBITDA-44.28-94.45-150.21-104.43-79.62-36.23-11.01-9.63-6.59
Non-Operating Income (Expense)5.294.428.928.744.674.384.705.060.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense16.9919.5816.294.592.071.760.991.302.39
Shares Outstanding50.0748.3148.2042.2441.7440.0235.2421.8417.22
Market Capitalization22.5222.52113.54949.341,232.871,748.73238.3889.5414.64

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.200.300.240.370.200.200.220.26
Gross Profit-0.20-0.30-0.24-0.37-0.20-0.20-0.22-0.26
Selling, General and Administrative Excl. Other11.079.0910.9313.1911.6645.1924.3729.23
Research and Development3.873.304.543.853.965.1213.6720.53
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-11.27-9.39-11.17-13.55-11.86-45.39-24.59-29.49
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense2.100.000.000.000.000.000.000.00
Net Income Before Taxes-10.73-8.60-10.33-12.54-10.81-44.22-23.40-27.60
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-10.73-8.60-10.33-12.54-10.81-44.22-23.40-27.60
Net Income From Continuing Operations-10.73-8.60-10.33-12.54-10.81-44.22-23.40-27.60
Net Income-10.73-8.60-10.33-12.54-10.81-44.22-23.40-27.60
EPS (Recurring)-0.19-0.18-0.21-0.26-0.22-0.92-0.48-0.57
EPS (Basic, Before Extraordinaries)-0.22-0.18-0.21-0.26-0.22-0.92-0.48-0.57
EPS (Diluted)-0.22-0.18-0.21-0.26-0.22-0.92-0.48-0.57
EBITDA-11.07-9.09-10.93-13.19-11.66-45.19-24.37-29.23
Non-Operating Income (Expense)2.650.790.841.011.051.171.181.89
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.484.074.075.374.404.585.225.74
Shares Outstanding50.0748.3148.3148.3148.3148.3148.3148.20
Market Capitalization22.5257.4981.6495.65140.5887.4472.46113.54

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments95.50128.57121.14201.01233.4493.5123.0819.8110.48
Short Term Receivables0.120.950.960.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.097.017.5410.2111.040.490.270.230.18
Total Current Assets97.71136.53129.63211.23244.4893.9923.3520.0410.66
Net Property, Plant & Equipment20.6520.9621.8522.9920.830.310.140.090.16
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.040.180.621.070.000.00--
Other Assets0.000.000.000.000.400.000.000.010.01
Total Assets118.36157.53151.66234.83266.7894.3023.4920.1410.83
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.100.100.060.090.000.00
Accounts Payable6.407.6510.574.027.130.910.450.290.42
Other Current Liabilities37.444.103.622.945.310.900.840.220.71
Total Current Liabilities43.8311.7514.207.0612.531.861.390.511.13
Long Term Debt0.000.000.000.040.140.230.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.120.080.000.200.190.000.000.000.00
Total Liabilities43.9511.8314.207.2912.872.101.390.511.13
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity74.40145.70137.47227.54253.9192.2022.1019.639.70
Total Shareholders Equity74.40145.70137.47227.54253.9192.2022.1019.639.70
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity74.40145.70137.47227.54253.9192.2022.1019.639.70
Total Liabilities & Stockholders Equity118.36157.53151.66234.83266.7894.3023.4920.1410.83
Book Value Per Share1.543.023.255.456.352.621.011.141.47
Tangible Book Value Per Share1.543.023.255.446.322.621.011.141.47
Full-Time Employees203029262411999
Price to Book Ratio0.390.686.115.956.892.615.140.752.32
Return on Assets-65.95-15.75-50.31-30.40-17.94-10.76-21.23-42.34-79.06
Return on Equity-82.66-17.19-53.27-31.67-18.71-11.08-22.20-44.72-84.07
Return on Invested Capital-122.27-16.71-70.72-33.50-12.75-6.85-20.96-33.41-122.81
Quick Ratio2.2311.629.1329.9119.5150.4016.8339.229.42
Current Ratio2.2311.629.1329.9119.5150.4016.8339.229.42

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-42.20-90.97-24.34-97.22-76.25-32.38-6.33-4.63-6.56
Depreciation1.060.941.131.531.300.530.020.060.07
Other Funds (Non Cash)16.9919.58-91.894.592.071.760.641.302.39
Funds from Operations-24.14-70.45-115.10-91.10-72.88-30.09-5.67-3.28-4.10
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-4.4338.20-1.839.08-4.63-0.100.290.76-0.67
Cash from Operating Activities-28.57-32.25-116.93-82.03-77.51-30.20-5.38-2.51-4.77
Capital Expenditures-0.55-0.58-0.10-0.41-2.71-22.210.00-0.020.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.36-0.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.55-0.58-0.10-0.41-2.71-22.210.36-0.020.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock1.29-0.24124.472.5647.80192.3475.455.8114.10
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00-0.060.00
Sale of Common Pref Stock1.29-0.24124.472.5647.80192.3475.455.8714.10
Proceedsfrom Stock Options1.29-0.330.000.0047.33189.8270.250.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities1.29-0.24124.472.5647.80192.3475.455.8114.10
Net Change in Cash-27.84-33.077.44-79.88-32.42139.9370.423.279.33
Free Cash Flow-29.13-32.83-117.03-82.44-80.23-52.41-5.38-2.53-4.77
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments78.2482.6886.5795.50106.08112.38
Short Term Receivables0.020.000.120.120.820.83
Inventories0.000.000.000.000.000.00
Other Current Assets1.791.041.272.092.011.60
Total Current Assets80.0683.7287.9697.71108.91114.82
Net Property, Plant & Equipment20.0020.1820.4020.6520.8220.56
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets100.06103.90108.37118.36129.73135.38
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable9.5239.2939.196.4046.0942.82
Other Current Liabilities32.420.870.9337.441.954.51
Total Current Liabilities41.9540.1640.1243.8348.0547.33
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.140.140.110.120.120.08
Total Liabilities42.0840.2940.2343.9548.1647.41
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity57.9863.6168.1474.4081.5787.97
Total Shareholders Equity57.9863.6168.1474.4081.5787.97
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity57.9863.6168.1474.4081.5787.97
Total Liabilities & Stockholders Equity100.06103.90108.37118.36129.73135.38
Book Value Per Share1.161.321.411.541.691.82
Tangible Book Value Per Share1.161.321.411.541.691.82
Full-Time Employees---20--
Price to Book Ratio0.390.841.101.171.600.69
Return on Assets-36.73-35.34-62.50-65.95-59.99-65.00
Return on Equity-60.48-55.78-79.59-82.66-85.44-88.95
Return on Invested Capital-18.50-13.52-15.16-16.85-13.25-50.27
Quick Ratio1.912.082.192.232.272.43
Current Ratio1.912.082.192.232.272.43

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-10.73-8.60-10.33-12.54-10.81-44.22
Depreciation0.210.240.240.370.130.22
Other Funds (Non Cash)3.484.074.075.374.404.58
Funds from Operations-7.04-4.29-6.02-6.80-6.27-39.42
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.950.43-2.86-2.950.0534.48
Cash from Operating Activities-6.09-3.85-8.88-9.75-6.22-4.95
Capital Expenditures-0.03-0.020.00-0.50-0.080.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.03-0.020.00-0.50-0.080.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.620.000.00-0.330.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.620.000.00-0.330.000.00
Proceedsfrom Stock Options1.620.000.00-0.330.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.07-0.02-0.050.000.000.00
Other Financing Activities Uses0.07-0.02-0.050.000.000.00
Cash from Financing Activities1.68-0.02-0.05-0.330.000.00
Net Change in Cash-4.44-3.89-8.93-10.58-6.30-4.95
Free Cash Flow-6.12-3.88-8.88-10.25-6.30-4.95

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.64%5.7M48.8M1.99M
2026-10-1511.95%5.6M46.9M2.00M
2026-09-3012.54%5.9M46.9M1.95M
2026-09-1513.14%6.2M47.3M321.77K
2026-08-3113.30%6.3M47.3M321.15K
2026-08-1413.34%6.3M47.3M354.99K
2026-07-3113.65%6.5M47.3M376.69K
2026-07-1513.18%6.2M47.3M395.27K
2026-06-3013.71%6.5M47.3M376.15K
2026-06-1513.90%6.6M47.3M390.21K
2026-05-2914.55%6.9M47.3M468.67K
2026-05-1514.14%6.7M47.3M518.71K
2026-04-3014.47%6.8M47.3M541.27K
2026-04-1515.31%6.9M45.3M633.63K
2026-03-3116.97%7.2M42.7M693.38K
2026-03-1317.15%7.3M42.7M853.56K
2026-02-2716.33%7.0M42.7M843.92K
2026-02-1316.70%7.1M42.7M922.30K
2026-01-3016.62%7.1M42.7M989.53K
2026-01-1516.82%7.2M42.7M1.18M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.450.1617.09573.000.000.887-0.0140.000
call1.000.000.050.045.4359170.000.299-0.0080.000
call1.500.000.050.056.4544860.000.263-0.0090.000
call2.000.000.050.057.3212780.000.246-0.0100.000
call2.500.000.050.047.9535180.000.236-0.0100.000
call3.000.002.150.059.29119.000.000.238-0.0120.000
call3.500.000.050.039.7161130.000.233-0.0130.000
put0.500.000.400.0617.11030.000.00-0.113-0.0140.000
put1.000.200.900.5519.57920.000.00-0.698-0.0080.000
put1.500.651.450.7025.5188.000.00-0.730-0.0100.000
put2.001.151.901.6021.7231.000.00-0.746-0.0110.000
put2.501.452.601.960.0001.000.00-0.755-0.0110.000
put3.001.803.402.380.0001.000.00-0.762-0.0120.000
put3.502.403.600.000.0000.000.00-0.767-0.0120.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-124Statement of changes in beneficial ownership of securities2026-11-09SEC
2026-11-123Initial statement of beneficial ownership of securities2026-11-08SEC
2026-11-128-KCurrent report2026-11-08SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-208-KCurrent report2026-10-20SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-228-KCurrent report2026-09-22SEC
2026-09-188-KCurrent report2026-09-17SEC
2026-07-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-298-KCurrent report2026-07-29SEC
2026-06-158-KCurrent report2026-06-11SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-28ARSAnnual report to security holders. 2025-12-31SEC
2026-04-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-11SEC
2026-04-288-KCurrent report2026-04-22SEC
2026-03-1210-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-128-KCurrent report2026-03-12SEC
2026-03-108-KCurrent report2026-03-10SEC
2026-02-198-KCurrent report2026-02-19SEC
2025-12-238-KCurrent report2025-12-19SEC
2025-12-228-K/A2025-10-21SEC
2025-12-188-KCurrent report2025-12-15SEC
2025-12-178-KCurrent report2025-12-12SEC
2025-12-05EFFECTEffectiveness filing by commission orderSEC
2025-12-05424B2SEC
2025-12-03CORRESPSEC
2025-12-038-KCurrent report2025-11-26SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09356.33K300
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-11640.75K300

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC4.09%
TWO SIGMA INVESTMENTS, LP3.54%
MARSHALL WACE, LLP3.31%
BlackRock, Inc.3.01%
GOLDMAN SACHS GROUP INC1.38%
GEODE CAPITAL MANAGEMENT, LLC1.27%
D. E. Shaw & Co., Inc.1.00%
GMT CAPITAL CORP0.93%
Squarepoint Ops LLC0.78%
ACADIAN ASSET MANAGEMENT LLC0.66%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.83%
VANGUARD EXTENDED MARKET INDEX FUND1.17%
Fidelity Extended Market Index Fund0.56%
iShares Micro-Cap ETF0.31%
VANGUARD HEALTH CARE INDEX FUND0.28%
Dimensional U.S. Small Cap ETF0.17%
Fidelity Total Market Index Fund0.17%
Goldman Sachs Absolute Return Tracker Fund0.17%
U.S. SMALL CAP PORTFOLIO0.15%
Fidelity Series Total Market Index Fund0.15%

OakChart. FLNA. Cached 15 minutes. Terms